AI-generated summary
The authors combined low level laser therapy at 640 nm with the antiretroviral drug efavirenz and tested the combination on HIV-infected TZM-bl cells in the laboratory. They report that the combination significantly reduced HIV infection, although cell morphology, proliferation and integrity assays showed undesirable effects on the cells.
- Who or what was studied
- TZM-bl cells, HIV-infected and uninfected, in vitro
- Wavelengths
- 640 nm
- Limits stated in the abstract
- This is a laboratory cell study, so the results do not show effects in humans or animals.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on linkinghub.elsevier.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 640 nm
- Energy density (fluence)
- 10 J/cm2
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Laser, Low-level laser therapy, Reactive oxygen species, Light-emitting diode, Wavelength. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.